IOL in SCT for hematologic malignancies

• For hematologic malignancies post-SCT, SF measured every 6 months only returned to normal after 5 years¹.
• An international expert panel (EBMT, European LeukemiaNet and International MDS Foundation) could not recommend a specific method to evaluate IOL in the SCT setting. The panel agreed that MDS patients with a transfusion history of >20 RBC units who are potential candidates for SCT should receive appropriate ICT prior to conditioning for SCT. In many patients SCT cannot be safely delayed because of relapse risk, but for those with lower risk, reducing IOL prior to SCT can be considered².
• Studies examining an impact of IOL in SCT for hematologic malignancies, and including an MVA or ROC analysis are shown under the IOL impact section.